Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Shock
Clinical narrative: deep vein thrombosis; Severe exacerbations of systemic capillary leak syndrome after covid-19 vaccination; Severe exacerbations of systemic capillary leak syndrome after covid-19 vaccination; Hypotensive shock; This literature-non-study case was reported in a literature article and describes the occurrence of CAPILLARY LEAK SYNDROME (Severe exacerbations of systemic capillary leak syndrome after covid-19 vaccination), CONDITION AGGRAVATED (Severe exacerbations of systemic capillary leak syndrome after covid-19 vaccination), SHOCK (Hypotensive shock) and DEEP VEIN THROMBOSIS (deep vein thrombosis) in a 46-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.      The patient's past medical history included Vaginal delivery (normal) in 2002, Amniotic fluid embolism (hypotension and edema) in 2002, Hypotension (systolic blood pressure was approximately 50mmHg) in 2018, Anasarca (after several days of upper respiratory symptoms) in 2018, Sepsis in 2018 and Capillary leak syndrome.   In February 2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In February 2021, the patient experienced CAPILLARY LEAK SYNDROME (Severe exacerbations of systemic capillary leak syndrome after covid-19 vaccination) (seriousness criteria hospitalization, medically significant and life threatening) and CONDITION AGGRAVATED (Severe exacerbations of systemic capillary leak syndrome after covid-19 vaccination) (seriousness criteria hospitalization and life threatening). February 2021, the patient experienced SHOCK (Hypotensive shock) (seriousness criteria hospitalization, medically significant and life threatening) and DEEP VEIN THROMBOSIS (deep vein thrombosis) (seriousness criteria hospitalization, medically significant and life threatening). The patient was hospitalized from sometime in February 2021 to sometime in February 2021 due to CAPILLARY LEAK SYNDROME, CONDITION AGGRAVATED and SHOCK, and then from sometime in February 2021 to sometime in February 2021 due to DEEP VEIN THROMBOSIS. The patient was treated with IMMUNOGLOBULINS NOS (IMMUNOGLOBULIN I.V) for Adverse event, at an unspecified dose and frequency; ANTIBIOTICS for Adverse event, at an unspecified dose and frequency and CORTICOSTEROIDS for Adverse event, at an unspecified dose and frequency. In February 2021, CAPILLARY LEAK SYNDROME (Severe exacerbations of systemic capillary leak syndrome after covid-19 vaccination), CONDITION AGGRAVATED (Severe exacerbations of systemic capillary leak syndrome after covid-19 vaccination), SHOCK (Hypotensive shock) and DEEP VEIN THROMBOSIS (deep vein thrombosis) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In February 2021, Adenovirus test: negative (Negative) Negative. In February 2021, Aspartate aminotransferase (5 u/l-34 u/l): 47 u/l (High) 47 U/L. In February 2021, Blood albumin (35 g/l-52 g/l): 20 g/l (Low) 20 g/L. In February 2021, Blood creatine phosphokinase (0.48 µkat/l-2.8 µkat/l): 23.19 µkat/l (High) 23.19 µkat/L. In February 2021, Blood creatinine (0.55 mg/dl-1.2 mg/dl): 1.5 mg/dl (High) 1.5 mg/dl and 132.63 µmol/l (High) 132.63 µmol/L. In February 2021, Blood immunoglobulin G (7.00 g/l-16.00 g/l): <2.70 (Low) <2.70 g/L. In February 2021, Blood lactic acid (0.5 mmol/l-2.2 mmol/l): 7.7 mmol/l (High) 7.7 mmol/L. In February 2021, Blood pressure systolic: 60 mm hg (Low) 60 mm Hg. In February 2021, Bordetella test: negative (Negative) Negative. In February 2021, Chlamydia test: negative (Negative) Negative. In February 2021, Haematocrit (0.341-0.449): 0.686 (High) 0.686. In February 2021, Haemoglobin (112 g/l-157 g/l): 233 g/l (High) 233 g/L. In February 2021, Heart rate: 120 beats/min. (High) 120 beats/min.. In February 2021, Human metapneumovirus test: negative (Negative) Negative. In February 2021, Human rhinovirus test: negative (Negative) Negative. In February 2021, Influenza A virus test: negative (Negative) Negative. In February 2021, Influenza B virus test: negative (Negative) Negative. In February 2021, Influenza virus test: negative (Negative) Negative. In February 2021, Mycoplasma test: negative (Negative) Negative. In February 2021, Platelet count (150.00 10^9/l-440.00 10^9/l): 213.00 10^9/l (normal) 2113.00 10^9/L. In February 2021, Red blood cell sedimentation rate (0 mm/hr-25 mm/hr): 1 mm/hr (normal) 1 mm/hr. In February 2021, Respiratory syncytial virus test: negative (Negative) Negative. In February 2021, SARS-CoV-2 test: negative (Negative) Negative for 229E, HKU1, NL63, and OC43 coronaviruses.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered CAPILLARY LEAK SYNDROME (Severe exacerbations of systemic capillary leak syndrome after covid-19 vaccination), CONDITION AGGRAVATED (Severe exacerbations of systemic capillary leak syndrome after covid-19 vaccination), SHOCK (Hypotensive shock) and DEEP VEIN THROMBOSIS (deep vein thrombosis) to be possibly related.    On an unspecified date in Feb-2021, patient presented to hospital with influenza-like syndrome, hypotension and tachycardia. During the hospitalization, the patient experienced anasarca, bilateral lower-extremity pain and a pericardial effusion. The patient gained 18 kgs of weight. Patient's additional treatment included vasopressors and Intravenous fluids. On an unspecified date, patient was discharged on day 7 of hospitalization.  Very limited information regarding this events has been provided at this time. Further information has been requested. Further information is not expected.   Most recent FOLLOW-UP information incorporated above includes: On 22-Jul-2021: Full text article received : clinical course of events, laboratory investigations, treatment details and medical history were added.; Sender's Comments: Very limited information regarding this events has been provided at this time. Further information has been requested. Further information is not expected.